Page 1,542«..1020..1,5411,5421,5431,544..1,5501,560..»

JPMorgan Chase & Co. Boosts Stake in iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem

Posted: June 10, 2017 at 3:45 am


Chaffey Breeze
JPMorgan Chase & Co. Boosts Stake in iShares NASDAQ Biotechnology Index (IBB)
The Cerbat Gem
iShares NASDAQ Biotechnology Index logo JPMorgan Chase & Co. raised its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 45.7% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned ...
iShares NASDAQ Biotechnology Index (IBB) Lifted to Buy at Vetr Inc.Sports Perspectives
iShares NASDAQ Biotechnology Index (IBB) Shares Bought by ...Chaffey Breeze
Verity Asset Management Inc. Takes Position in iShares NASDAQ Biotechnology Index (IBB)Transcript Daily
BBNS
all 13 news articles »

Read the original here:
JPMorgan Chase & Co. Boosts Stake in iShares NASDAQ Biotechnology Index (IBB) - The Cerbat Gem

Posted in Biotechnology | Comments Off on JPMorgan Chase & Co. Boosts Stake in iShares NASDAQ Biotechnology Index (IBB) – The Cerbat Gem

Cell Transplantation : The Regenerative Medicine Journal

Posted: June 10, 2017 at 3:44 am

Future issues are now being published by SAGE. Please visit their website for new issues:

https://us.sagepub.com/en-us/nam/cell-transplantation/journal203416

(Scroll down to view tables of contents for all Volumes and Issues)

Volume 26, Number 6 Reviews Pig-to-Primate Islet Xenotransplantation: Past, Present, and Future 925Zhengzhao Liu,Wenbao Hu, Tian He,Yifan Dai, Hidetaka Hara, RitaBottino, David K. C. Cooper,Zhiming Cai, andLisha Mou

Using Electrical Stimulation to Enhance the Efficacy of Cell Transplantation Therapies for Neurodegenerative Retinal Diseases: Concepts, Challenges, and Future Perspectives 949Abby LeighManthey, Wei Liu,Zhi Xin Jiang, MarcusHiu Kong Lee, Jian Ji, Kwok-Fai So, JimmyShiu Ming Lai, Vincent Wing Hong Lee, and Kin Chiu

Original Contributions

OlfactoryEnsheathing Cells Inhibit Gliosis in Retinal Degeneration by Downregulation of the Mller Cell Notch Signaling Pathway 967JingXie,Shujia Huo,Yijian Li,Jiaman Dai,Haiwei Xu, and Zheng Qin Yin

EarlySubretinal Allograft Rejection Is Characterized by Innate Immune Activity 983Kevin P. Kennelly, Toby M. Holmes, Deborah M. Wallace, ClionaOFarrelly, and David J. Keegan

Human Dental Pulp Stem Cells Are More Effective Than Human Bone Marrow-Derived Mesenchymal Stem Cells in Cerebral Ischemic Injury 1001Miyeoun Song, Jae-Hyung Lee,Jinhyun Bae,Youngmin Bu, andEun-Cheol Kim

The Timing of Immunomodulation Induced by Mesenchymal Stromal Cells Determines the Outcome of the Graft in Experimental RenalAllotransplantation 1017Ana Merino, Elia Ripoll, Laura de Ramon,Nuria Bolaos, Montserrat Goma, OriolBestard,Nuria Lloberas,Josep M.Grinyo, and JuanTorras Ambrs

Human Umbilical Cord Mesenchymal Stem Cells Inhibit T Follicular Helper Cell Expansion Through the Activation ofiNOS in Lupus-Prone B6.MRL-Faslpr Mice 1031Zhuoya Zhang,Ruihai Feng,Lingying Niu,Saisai Huang, Wei Deng,Bingyu Shi,Genhong Yao,Weiwei Chen,Xiaojun Tang, Xiang Gao,Xuebing Feng, andLingyun Sun

CD34 Antigen and the MPL Receptor Expression Defines a Novel Class of Human Cord Blood-Derived Primitive Hematopoietic Stem Cells 1043Yoshikazu Matsuoka, Masaya Takahashi, KeisukeSumide, Hiroshi Kawamura,Ryusuke Nakatsuka, Tatsuya Fujioka, and YoshiakiSonoda

Long-Term Follow-Up of Patients After Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis 1059Ja Kyung Kim, Soo-Jeong Kim, Yuri Kim, YongEun Chung, YoungNyun Park, Hyun Ok Kim,Jin Seok Kim,Mi-Suk Park, IsaoSakaida, Do Young Kim, Jung Il Lee, SangHoon Ahn, KwanSik Lee, and Kwang-HyubHan

Calcium Concentration in Culture Medium as a Nondestructive and Rapid Marker of Osteogenesis 1067Yohei Tanikake, ManabuAkahane, Akira Furukawa,Yasuaki Tohma, Yusuke Inagaki, Tsutomu Kira, andYasuhito Tanaka

Cisplatin-ImpairedAdipogenic Differentiation of Adipose Mesenchymal Stem Cells 1077Yu-Hsun Chang, Hwan-Wun Liu, Tang-Yuan Chu, Yao-Tseng Wen,Rong-Kung Tsai, and Dah-Ching Ding

Effects of Different Cell-Detaching Methods on the Viability and Cell Surface Antigen Expression of Synovial Mesenchymal Stem Cells 1089Kunikazu Tsuji,Miyoko Ojima, KojiOtabe,Masafumi Horie, Hideyuki Koga, Ichiro Sekiya, and TakeshiMuneta

Human Muscle Precursor Cells Overexpressing PGC-1a Enhance Early Skeletal Muscle Tissue Formation 1103DeanaHaralampieva, SouzanSalemi, IvanaDinulovic,Tullio Sulser, Simon M.Ametamey, ChristophHandschin, and DanielEberli

Volume 26, Number 5

GeoffreyRaisman, 19392017: Opening a Scientific Door and Giving Hope 733 Paul R.Sanberg

Review

Conceptual Design and Procedure for an AutonomousIntramyocardial Injection Catheter 735 Weyland Cheng and Peter K. Law

Original Contributions

Hydrogen Sulfide Reduces Recruitment of CD11b+Gr-1+Cells in Mice With Myocardial Infarction 753 Ting Wu, Hua Li, Bing Wu, Lei Zhang, San-wu Wu,Jia-ning Wang, and You-en Zhang

Developing a Rapid Algorithm to Enable Rapid Characterization of Alginate Microcapsules 765 Ka Hei Chan, Rahul Krishnan, Michael Alexander, and Jonathan R. T.Lakey

StemCell Keep Is Effective for Cryopreservation of Human Embryonic Stem Cells byVitrification 773 Akemi Ota, Kazuaki Matsumura, Jun-Jae Lee,Shoichiro Sumi, andSoung-Hyu Hyon

In VitroMicrovibration Increases Implantation Rate After Embryonic Cell Transplantation 789 VladimirIsachenko, KarlSterzik, RobertMaettner,Evgenia Isachenko,Plamen Todorov,Gohar Rahimi, PeterMallmann, ErwinStrehler, IgorPereligin, Jos LuisAlabart, and MarkusMerzenich

Changes in Sexual Behavior ofOrchidectomized Rats Under Influence ofAllotransplantation of Testicular Interstitial Cell Suspension 795 Bo Deng, TatyanaBondarenko, andOleksandr Pakhomov

Precise Regulation of miR-210 Is Critical for the Cellular Homeostasis Maintenance and Transplantation Efficacy Enhancement of Mesenchymal Stem Cells in Acute Liver Failure Therapy 805 Yingxia Liu,Yongjia Xiong,Feiyue Xing,Hao Gao,Xiaogang Wang,Liumin He,Chaoran Ren, Lei Liu, Kwok-Fai So, andJia Xiao

Human Muse Cells,Nontumorigenic Pluripotent-Like Stem Cells, Have Liver Regeneration Capacity Through Specific Homing and Cell Replacement in a Mouse Model of Liver Fibrosis 821 Masahiro Iseki, YoshihiroKushida,Shohei Wakao, Takahiro Akimoto,Masamichi Mizuma,Fuyuhiko Motoi,Ryuta Asada,Shinobu Shimizu, MichiakiUnno, GregorioChazenbalk, and MariDezawa

Phenotypical and Functional Characteristics of In Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells From Patients With Systematic Sclerosis 841 ChiaraCapelli, EleonoraZaccara, Paola Cipriani, Paola Di Benedetto, WandaMaglione, RominaAndracco, Gabriele Di Luca, FrancescaPignataro, RobertoGiacomelli, MartinoIntrona,ClaudioVitali, and Nicoletta Del Papa

Are Adipose-Derived Stem Cells From LiverFalciform Ligaments Another Possible Source of Mesenchymal Stem Cells? 855 Sang Woo Lee, JaeUk Chong,Seon Ok Min,Seon YoungBak, and KyungSik Kim

Effect of Bone Marrow Aspirate ConcentratePlatelet-Rich Plasma on Tendon-Derived Stem Cells and Rotator Cuff Tendon Tear 867 SunJeong Kim, Da Hyun Song, JongWook Park, Silvia Park, and Sang Jun Kim

Human Bone Progenitor Cells for Clinical Application: What Kind of Immune Reaction Does Fetal Xenograft Tissue Trigger in Immunocompetent Rats? 879 Tanja C.Hausherr,Katja Nuss, Eric Thein, Lee A. Applegate, and Dominique P.Pioletti

Clinical Study ofNeuroRegen Scaffold Combined With Human Mesenchymal Stem Cells for the Repair of Chronic Complete Spinal Cord Injury 891 Yannan Zhao,Fengwu Tang,Zhifeng Xiao,Guang Han,NuoWang, Na Yin, Bing Chen,Xianfeng Jiang, Chen Yun,Wanjun Han, Changyu Zhao,Shixiang Cheng, Sai Zhang, andJianwu Dai

Transgenic Expression of Glucagon-Like Peptide-1 (GLP-1) and Activated Muscarinic Receptor (M3R) Significantly Improves Pig Islet Secretory Function 901 Nizar I.Mourad, AndreaPerota,Daela Xhema, Cesare Galli, and PierreGianello

Transplantation of Cultured Olfactory Bulb Cells Prevents Abnormal Sensory Responses During Recovery From Dorsal Root Avulsion in the Rat 913 Andrew Collins, Daqing Li, Stephen B. McMahon, GeoffreyRaisman, and Ying Li

SPECIAL ISSUE 24th MEETING OF THE AMERICAN SOCIETY FOR NEURAL THERAPY AND REPAIR (ASNTR)Recent Progress in Cell Therapy and Regenerative Medicine for Neurological Disorders: Introduction to the ASNTR Special Issue From the 2016 Meeting 529 Cesar V.Borlongan

Is Immune Modulation the Mechanism Underlying the Beneficial Effects of Amniotic Cells and Their Derivatives in Regenerative Medicine? 531 Antonietta R.Silini, MartaMagatti, AnnaCargnoni, and OrnellaParolini

Human Amnion Epithelial Cells Protect Against White Matter Brain Injury After Repeated Endotoxin Exposure in the Preterm Ovine Fetus 541 TamaraYawno,Tharani Sabaretnam,Jingang Li, Courtney McDonald, Rebecca Lim, Graham Jenkin, Euan M. Wallace, and Suzanne L. Miller

Repetitive and Prolonged Omega-3 Fatty Acid Treatment After Traumatic Brain Injury Enhances Long-Term Tissue Restoration and Cognitive Recovery 555 Hongjian Pu,Xiaoyan Jiang,Zhishuo Wei,Dandan Hong,Sulaiman Hassan,Wenting Zhang,Jialin Liu,Hengxing Meng,Yejie Shi, Ling Chen, and Jun Chen

A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain 571 Kuo-Jen Wu,Seong-Jin Yu,Kak-Shan Shia,Chien-Huang Wu, Jen-Shin Song,Hsuan-HaoKuan, Kai-ChiaYeh,Chiung-Tong Chen,Eunkyune Bae, and Yun Wang

A Comparative Study of Three Different Types of Stem Cells for Treatment of Rat Spinal Cord Injury 585 JiriRuzicka, LuciaMachova-Urdzikova, JohnGillick, TakashiAmemori,Nataliya Romanyuk,Kristyna Karova,Kristyna Zaviskova, JanaDubisova,Sarka Kubinova, RajMurali, EvaSykova,Meena Jhanwar-Uniyal, andPavla Jendelova

Fate of Neural Progenitor Cells Transplanted Into Jaundiced andNonjaundiced Rat Brains 605 Fu-Chen Yang, Sean M. Riordan, Michelle Winter, Li Gan, Peter G. Smith, Jay L. Vivian, Steven M. Shapiro, and John A. Stanford

Real-Time Intraoperative MRI Intracerebral Delivery of Induced Pluripotent Stem Cell-Derived Neurons 613 Scott C.Vermilyea,Jianfeng Lu, Miles Olsen, Scott Guthrie,Yunlong Tao, Eva M.Fekete, Marissa K. Riedel, Kevin Brunner, Carissa Boettcher,Viktorya Bondarenko, Ethan Brodsky, Walter F. Block, Andrew Alexander, Su-Chun Zhang, and Marina E.Emborg

A Comparison of Exogenous Labels for the Histological Identification of Transplanted Neural Stem Cells 625 Francesca J. Nicholls, Jessie R. Liu, and MichelModo

Transplantation of Mesenchymal Stromal Cells in Patients With Amyotrophic Lateral Sclerosis: Results of Phase I/IIa Clinical Trial 647 EvaSykov, PetrRychmach, IvanaDrahordov,imona Konrdov,Kateina Rikov, IvanVoek,Serhiy Forostyak,Ale Homola, and MartinBojar

Step Sequence Is a Critical Gait Parameter of Unilateral 6-OHDA Parkinsons Rat Models 659 Heather A. Baldwin,Pyry P.Koivula, Julie C.Necarsulmer, Keith W. Whitaker, and Brandon K. Harvey

Brilliant Blue G, But Not Fenofibrate, Treatment RevertsHemiparkinsonian Behavior and Restores Dopamine Levels in an Animal Model of Parkinsons Disease 669 Enas G.Ferrazoli,Hllio D.N. de Souza, Isis C.Nascimento,gatha Oliveira-Giacomelli,Telma T.Schwindt, Luiz R.Britto, and Henning Ulrich

A Subpopulation of Dopaminergic NeuronsCoexpresses Serotonin in Ventral Mesencephalic Cultures But Not AfterIntrastriatal Transplantation in a Rat Model of Parkinsons Disease 679 Stefano Di Santo, Stefanie Seiler,Anglique D.Ducray, Morten Meyer, and Hans RudolfWidmer

Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimers Disease 693 Scott E. Counts and Elliott J.Mufson

Abstracts for the 24th Annual Meeting of the American Society for Neural Therapy and Repair 703

Volume 26, Number 3

Precision Therapy: Cell Therapy and Development of New Drugs 379 ShinnZong Lin

The Regulatory Effects of Transforming Growth Factor- on Nerve Regeneration 381 Shiying Li,Xiaosong Gu, and Sheng Yi

GSK-3 Inhibition Induced Neuroprotection, Regeneration, and Functional Recovery After Intracerebral Hemorrhagic Stroke 395 Yingying Zhao, ZhengZachory Wei, JamesYa Zhang,Yongbo Zhang,Soonmi Won,Jinmei Sun, Shan Ping Yu,Jimei Li, and Ling Wei

Neuroprotection of Granulocyte Colony-Stimulating Factor for Early Stage Parkinsons Disease 409 Sheng-Tzung Tsai, Sung-Chao Chu, Shu-Hsin Liu, Cheng-Yoong Pang, Ting-WenHou, Shinn-Zong Lin, and Shin-Yuan Chen

Chondrogenic Differentiation of Mesenchymal Stem Cells in Three-Dimensional Chitosan Film Culture 417 Tsai-Jung Lu, Fang-Yao Chiu, Hsiao-Ying Chiu, Ming-Chau Chang, and Shih-Chieh Hung

Pre-S2 Mutant-Induced Mammalian Target of Rapamycin Signal Pathways as Potential Therapeutic Targets for Hepatitis B Virus-Associated Hepatocellular Carcinoma 429 Chiao-FangTeng, Han-Chieh Wu,Woei-Cherng Shyu, Long-BinJeng, andIh-Jen Su

Mesenchymal Stem Cells: The Magic Cure for Intraventricular Hemorrhage? 439 Won Soon Park, So YoonAhn, Se In Sung,Jee-YinAhn, and Yun Sil Chang

Commercial Production of Autologous Stem Cells and Their Therapeutic Potential for Liver Cirrhosis 449 Yi-Chun Lin,Horng-Jyh Harn, Po-Cheng Lin, Ming-Hsi Chuang, Chun-Hung Chen, Shinn-Zong Lin, andTzyy-WenChiou

Novel Therapeutic Transplantation of Induced Neural Stem Cells for Stroke 461 Toru Yamashita,Wentao Liu, Yoshiaki Matsumura,Ryosuke Miyagi, YunZhai,Momoko Kusaki,Nozomi Hishikawa,Yasuyuki Ohta, Sung Min Kim, Tae HwanKwak, DongWook Han, and Koji Abe

Neural Stem Cell-Conditioned Medium Suppresses Inflammation and Promotes Spinal Cord Injury Recovery 469 Zhijian Cheng, Dale B. Bosco, Li Sun,Xiaoming Chen,Yunsheng Xu,Wenjiao Tai, Ruth Didier, Jinhua Li,Jianqing Fan,Xijing He, and Yi Ren

Cell Therapy Regulation in Taiwan 483 Yuan-Chuan Chen,Hwei-Fang Cheng, and Ming-KungYeh

Adiponectin Potentially Contributes to theAntidepressive Effects ofBaduanjin Qigong Exercise in Women With Chronic Fatigue Syndrome-Like Illness 493 Jessie S. M. Chan, Ang Li, Siu-man Ng, Rainbow T. H. Ho,Aimin Xu,Tzy-jyun Yao, Xiao-Min Wang, Kwok-Fai So, and Cecilia L. W. Chan

Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I/IIa Clinical Study 503 Yun-An Tsai, Ren-Shyan Liu,Jiing-FengLirng, Bang-Hung Yang, Chin-Hao Chang, Yi-Chen Wang, Yu-Shan Wu, Jennifer Hui-Chun Ho, Oscar K. Lee, and Bing-Wen Soong

Imbalanced Production of Reactive Oxygen Species and Mitochondrial Antioxidant SOD2 inFabry Disease-Specific Human Induced Pluripotent Stem Cell-Differentiated Vascular Endothelial Cells 513 Wei-Lien Tseng, Shih-Jie Chou, Huai-Chih Chiang, Mong-Lien Wang, Chian-Shiu Chien,Kuan-Hsuan Chen,Hsin-BangLeu,Chien-Ying Wang,Yuh-Lih Chang, Yung-Yang Liu,Yuh-Jyh Jong, Shinn-Zong Lin, Shih-HwaChiou,Shing-Jong Lin, and Wen-Chung Yu

Volume 26, Number 2

Human Adipose-Derived Stem Cells Suppress Elastase-Induced Murine Abdominal Aortic Inflammation and Aneurysm Expansion Through Paracrine Factors 173 Jie Xie, Thomas J. Jones,Dongni Feng, Todd G. Cook, Andrea A. Jester, Ru Yi,Yameena T. Jawed, CliffordBabbey, Keith L. March, and Michael P. Murphy

CXCR4 Overexpression in Human Adipose Tissue-Derived Stem Cells Improves Homing and Engraftment in an Animal Limb Ischemia Model 191 MiJung Kim, Dong-Ik Kim,Eun Key Kim, and Chan-Wha Kim

ALLogeneic HeartSTem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design 205 Tarun Chakravarty, Raj R.Makkar, Deborah D.Ascheim, Jay H. Traverse, Richard Schatz, AnthonyDeMaria, Gary S. Francis, Thomas J.Povsic, Rachel R. Smith, Joao A. Lima, Janice M.Pogoda, LindaMarbn, and Timothy D. Henry

A Nerve Conduit Containing a Vascular Bundle and Implanted With Bone Marrow Stromal Cells and Decellularized Allogenic Nerve Matrix 215 YukitoshiKaizawa,Ryosuke Kakinoki,Ryosuke Ikeguchi,Soichi Ohta, Takashi Noguchi,Hisataka Takeuchi, Hiroki Oda, HirofumiYurie, and Shuichi Matsuda

Bone Marrow Stromal Cells Combined With SodiumFerulate andn-Butylidenephthalide Promote the Effect of Therapeutic Angiogenesis via Advancing Astrocyte-Derived Trophic Factors After Ischemic Stroke 229 Qian Zhang, Zhen-Wei Chen, Yong-Hua Zhao, Bo-Wen Liu,Nai-Wei Liu, Chien-ChihKe, and Hong-Mei Tan

Secondary Release of Exosomes From Astrocytes Contributes to the Increase in Neural Plasticity and Improvement of Functional Recovery After Stroke in Rats Treated With Exosomes Harvested From MicroRNA 133b-Overexpressing Multipotent Mesenchymal Stromal Cells 243 Hongqi Xin,Fengjie Wang,Yanfeng Li, Qing-e Lu, Wing Lee Cheung, Yi Zhang, Zheng Gang Zhang, and MichaelChopp

Efficacy of Two Delivery Routes for Transplanting Human Neural Progenitor Cells (NPCs) Into the Spastic HanWistar Rat, a Model of Ataxia 259 Toni L.Uhlendorf, Ruslan L.Nuryyev, Alex O.Kopyov, Jessica Ochoa, ShahabYounesi, Randy W. Cohen, and Oleg V.Kopyov

Establishment and Characterization of Immortalized Minipig Neural Stem Cell Line 271 Sung S. Choi,Seung-Bin Yoon, Sang-Rae Lee, Sun-Uk Kim, YoungJoo Cha, Daniel Lee,Seung U. Kim,Kyu-Tae Chang, and Hong J. Lee

Safety of Intra-Arterial Injection With Tumor-Activated T Cells to the Rabbit Brain Evaluated by MRI and SPECT/CT 283 Johan Lundberg, EmmaJussing, Zhenjiang Liu,Qingda Meng, Martin Rao, ErikSamn,Rikard Grankvist, PeterDamberg, ErnestDodoo, MarkusMaeurer, andStaffan Holmin

Significantly Accelerated Wound Healing of Full-Thickness Skin Using a Novel Composite Gel of Porcine Acellular Dermal Matrix and Human Peripheral Blood Cells 293 Vijay K. Kuna, Arvind M. Padma,Joakim Hkansson, JanNygren, RobertSjback,Sarunas Petronis, andSuchitra Sumitran-Holgersson

Human Recombinant Antithrombin (ATryn) Administration Improves Survival and Prevents Intravascular Coagulation After Intraportal Islet Transplantation in a Piglet Model 309 ValeryGmyr, Caroline Bonner, ErickaMoerman, AntoineTournoys, NathalieDelalleau, AudreyQuenon, JulienThevenet, MikaelChetboun, Julie Kerr-Conte, FranoisPattou, Thomas Hubert, andMerce Jourdain

Monocyte-Derived Dendritic Cells Impair Early Graft Function Following Allogeneic Islet Transplantation 319 Kevin V. Chow, Emma M. Carrington,Yifan Zhan, Andrew M. Lew, and Robyn M. Sutherland

Thrombospondin-1-Derived Peptide RFYVVMWK Improves the Adhesive Phenotype of CD34+ Cells From Atherosclerotic Patients With Type 2 Diabetes 327 SylvieCointe, ricRhaume, Catherine Martel, Olivier Blanc-Brude,Evemie Dub, Florence Sabatier, FranoiseDignat-George, Jean-Claude Tardif, and ArnaudBonnefoy

Fetal Tissues Tested for Microbial Sterility by Culture- and PCR-Based Methods Can be Safely Used in Clinics 339 Yakov Vitrenko,Iryna Kostenko,Kateryna Kulebyakina,Alla Duda,Mariya Klunnyk, and KhrystynaSorochynska

Adult-Derived Human Liver Stem/Progenitor Cells Infused 3 DaysPostsurgery Improve Liver Regeneration in a Mouse Model of Extended Hepatectomy 351 Astrid Herrero, JuliePrigent, Catherine Lombard,Valrie Rosseels, MartineDaujat-Chavanieu,Karine Breckpot, MustaphaNajimi,Gisle Deblandre, and Etienne M.Sokal

-Catenin Accumulation Is Associated With Increased Expression ofNanog Protein and Predicts Maintenance of MSC Self-Renewal 365 Sang-Jin Yu, Hyun-Je Kim,Eui Seok Lee, Chung-Gyu Park, SuJin Cho, andSoung-Hoo Jeon

Volume 26, Number 1

Original Contributions

Identification of Donor Origin and Condition of Transplanted IsletsIn Situ in the Liver of a Type 1 Diabetic Recipient 1Cornelis R. van der Torren, Jessica S.Suwandi,DaHae Lee, Ernst-Jan T.vant Wout, GabyDuinkerken,Godelieve Swings,Arend Mulder, Frans H. J.Claas,Zhidong Ling, Pieter Gillard, BartKeymeulen, Peterint Veld, and Bart O.Roep

Physiologic Doses of Bilirubin Contribute to Tolerance of Islet Transplants by Suppressing the Innate Immune Response 11Christopher A. Adin, Zachary C.VanGundy, Tracey L. Papenfuss, Feng Xu, MostafaGhanem, JonathanLakey, and Gregg A. Hadley

Active Subjects With Autoimmune Type 1 Diabetes Have Better Metabolic Profiles Than Sedentary Controls 23M.Adamo, R.Codella, F. Casiraghi, A.Ferrulli, C.Macri, E.Bazzigaluppi, I.Terruzzi, L.Inverardi, C.Ricordi, and L.Luzi

Effect of Manufacturing Procedures on Human Islet Isolation From DonorPancreata Standardized by the North American Islet Donor Score 33Chun-Chieh Yeh, Ling-jia Wang, James J.McGarrigle, Yong Wang,Chien-Chang Liao, MustafaOmami, Arshad Khan, MohammadNourmohammadzadeh, Joshua Mendoza-Elias, Benjamin McCracken,Enza Marchese, BarbaraBarbaro, and JoseOberholzer

Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Critical Limb Ischemia in Diabetic Nude Rats 45Lu Liang,Zongjin Li, Tao Ma,Zhibo Han,Wenjing Du,Jie Geng,Honghong Jia, Meng Zhao,Jimin Wang,Bingjing Zhang,Jie Feng,Lanzhen Zhao, AlainRupin,Youwei Wang, andZhong Chao Han

Excluding Anti-cytomegalovirus Immunoglobulin M-Positive Cord Blood Units Has a Minimal Impact on the Korean Public Cord Blood Bank Inventory 63Sue Shin,Eun Youn Roh,Sohee Oh,Eun Young Song,Eui Chong Kim, and Jong Hyun Yoon

Control of IBMIR Induced by Fresh and Cryopreserved Hepatocytes by Low Molecular Weight Dextran Sulfate Versus Heparin 71Elisabet Gustafson, Sana Asif, HudaKozarcanin, GracielaElgue,Staffan Meurling, Kristina N.Ekdahl, and Bo Nilsson

Poor Mobilization in T-Cell-Deficient Nude Mice Is Explained by Defective Activation of Granulocytes and Monocytes 83MarcinWysoczynski, MateuszAdamiak,Malwina Suszynska, Ahmed Abdel-Latif, JaninaRatajczak, andMariusz Z.Ratajczak

Differences inTfh Cell Response Between the Graft and Spleen With Chronic Allograft Nephropathy 95Jian Shi,Xianlin Xu,Fengbao Luo,Qianqian Shi,Xiaozhou He, and Ying Xia

Improved Transplanted Stem Cell Survival in a Polymer Gel Supplemented With Tenascin C Accelerates Healing and Reduces Scarring of Murine Skin Wounds 103Cecelia C. Yates, AustinNuschke, Melanie Rodrigues, Diana Whaley, Jason J.Dechant, Donald P. Taylor, and Alan Wells

Effect of Gelatin on Osteogenic Cell Sheet Formation Using Canine Adipose-Derived Mesenchymal Stem Cells 115Ah young Kim,Yongsun Kim,Seung Hoon Lee,Yongseok Yoon, Wan-Hee Kim, and Oh-Kyeong Kweon

Biliary Polyunsaturated Fatty Acids andTelocytes in Gallstone Disease 125Artur Pasternak,Jolanta Bugajska,Mirosaw Szura, Jerzy A.Walocha, AndrzejMatyja,Mariusz Gajda, KrystynaSztefko, and Krzysztof Gil

Cellular Evidence ofTelocytes as Novel Interstitial Cells Within the Magnum of Chicken Oviduct 135Ping Yang,Xudong Zhu,Lingling Wang,Nisar Ahmed,Yufei Huang, Hong Chen, Qian Zhang,Shakeeb Ullah,Tengfei Liu,Dawei Guo,Sarfaraz AhmedBrohi, andQiusheng Chen

Pivotal Role of Brain-Derived Neurotrophic Factor Secreted by Mesenchymal Stem Cells in Severe Intraventricular Hemorrhage in Newborn Rats 145So YoonAhn, Yun Sil Chang, Dong Kyung Sung, Se In Sung,Jee-YinAhn, and Won Soon Park

Intramyocardially Transplanted Neonatal Cardiomyocytes (NCMs) Show Structural and Electrophysiological Maturation and Integration and Dose-Dependently Stabilize Function of Infarcted Rat Hearts 157MartinaMaass, BenjaminKrausgrill, SimonEschrig, TobiasKaluschke,Katja Urban, GabrielPeinkofer, Tobias G.Plenge, SimonOeckenpohler, MartinRaths, DennisLadage, MarcelHalbach,Jurgen Hescheler, andJochen Muller-Ehmsen

Excerpt from:
Cell Transplantation : The Regenerative Medicine Journal

Posted in Cell Medicine | Comments Off on Cell Transplantation : The Regenerative Medicine Journal

Removal of aging cells could extend human life – Medical Xpress

Posted: June 10, 2017 at 3:44 am

June 9, 2017 Clearance of SnCs by GCV reduces the development of post-traumatic OA. Credit: UNIST

A recent study, led by an international team of researchers confirms that targeted removal of senescent cells (SnCs), accumulated in many vertebrate tissues as we age, contribute significantly in delaying the onset of age-related pathologies.

This breakthrough research has been led by Dr. Chaekyu Kim of the Johns Hopkins University School of Medicine, who is now at UNIST, and Dr. Ok Hee Jeon of the Johns Hopkins University School of Medicine in collaborations with the Mayo Clinic College of Medicine, the Buck Institute for Research on Aging, the University Medical Center Groningen, Unity Biotechnology, Inc., and the University of California, Berkeley.

In the study, the research team presented a novel pharmacologic candidate that alleviates age-related degenerative joint conditions, such as osteoarthritis (OA) by selectively destroying SnCs. Their findings, published April 24th in Nature Medicine (Impact Factor: 30.357), suggest that the selective removal of old cells from joints could reduce the development of post-traumatic OA and allow new cartilage to grow and repair joints.

Senescent cells (SnCs) accumulate with age in many vertebrate tissues and are present at sites of age-related pathlogy. Although these cells play an essential role in wound healing and injury repair, they may also promote cancer incidence in tissues. For instance, in articular joints, such as the knee and cartilage tissue, SnCs often are not cleared from the area after injury, thereby contributing to OA development.

To test the idea that SnCs might play a causative role in OA, the research team took both younger and older mice and cut their anterior cruciate ligaments (ACL) to minic injury. They, then, administered injections of an experimental drug, named UBX0101 to selectively remove SnCs after anterior cruciate ligament transection (ACLT) surgery.

Preclinical studies in mice and human cells suggested that the removal of SnCs significantly reduced the development of post-traumatic OA and related pain and created a prochondrogenic environment for new cartilage to grow and repair joints. Indeed, the research team reported that aged mice did not exhibit signs of cartilage regeneration after treatment with UBX0101 injections,

According to the research team, the relevance of their findings to human disease was validated using chondrocytes isolated from arthritic patients. The research team notes that their findings provide new insights into therapies targeting SnCs for the treatment of trauma and age-related degenerative joint disease.

Prior to this study, Johns Hopkins Technology Ventures (JHTV) granted UNITY Biotechnology Inc. the right to use the intellectual property around the senescent cell technology. UNITY is a company aiming to develop therapeutics that address age-related diseases. Last October, the company announced $116 million in Series B funding from some of the big names in venture capital, including Amazon CEO Jeff Bezo's venture fund Bezos Expeditions, Mayo Clinic Ventures, Venrock, and ARCH Venture Partners. UNITY has completed a rigorous screening and preclinical testing process of candidate drugs, discovered in this study, and is launching a new clinical trial to assess its first drug, for patients with osteoarthritis of the knee this year.

Explore further: Clearing out old cells could extend joint health, stop osteoarthritis

More information: Ok Hee Jeon et al, Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment, Nature Medicine (2017). DOI: 10.1038/nm.4324

In a preclinical study in mice and human cells, researchers report that selectively removing old or 'senescent' cells from joints could stop and even reverse the progression of osteoarthritis.

Researchers at Mayo Clinic have reported a causal link between senescent cellscells that accumulate with age and contribute to frailty and diseaseand osteoarthritis in mice. Their findings appear online in The Journals ...

Among patients with knee osteoarthritis, an injection of a corticosteroid every three months over two years resulted in significantly greater cartilage volume loss and no significant difference in knee pain compared to patients ...

Mayo Clinic researchers have uncovered three new agents to add to the emerging repertoire of drugs that aim to delay the onset of aging by targeting senescent cells - cells that contribute to frailty and other age-related ...

Injury to the anterior cruciate ligament (ACL) in the knee frequently leads to early-onset osteoarthritis, a painful condition that can occur even if the patient has undergone ACL reconstruction to prevent its onset. A new ...

Dear Mayo Clinic: I'm interested in the new procedure approved by the U.S. Food and Drug Administration that can repair cartilage in the knee. How does it work? Who's a good candidate for this procedure?

(Medical Xpress)A large team of researchers from the Netherlands, Italy and the U.S. has found a possible explanation for the injury and death to patients in a clinical trial held last year in France. In their paper published ...

(HealthDay)Exercise doesn't just trim your tummy. It may also improve bone thickness, boost bone quality, and whittle away the fat found inside bones, new animal research suggests.

Drexel University and Georgia Institute of Technology researchers have discovered how the Rad52 protein is a crucial player in RNA-dependent DNA repair. The results of their study, published today in Molecular Cell, reveal ...

Despite many studies looking at which bread is the healthiest, it is still not clear what effect bread and differences among bread types have on clinically relevant parameters and on the microbiome. In the journal Cell Metabolism ...

Yale scientists produced increased grooming behavior in mice that may model tics in Tourette syndrome and discovered these behaviors vanish when histaminea neurotransmitter most commonly associated with allergiesis ...

Some bodily activities, sleeping, for instance, mostly occur once every 24 hours; they follow a circadian rhythm. Other bodily functions, such as body temperature, cognitive performance and blood pressure, present an additional ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read the original:
Removal of aging cells could extend human life - Medical Xpress

Posted in Cell Medicine | Comments Off on Removal of aging cells could extend human life – Medical Xpress

Stem Cell Therapy: Repair and Regenerate Our Bodies – Live … – Live Trading News

Posted: June 10, 2017 at 3:44 am

Stem Cell Therapy: Repair and Regenerate Our Bodies

$USRM

Stem Cells 101: The primary purpose of stem cells is to maintain, heal and regenerate tissues wherever they reside in the body. This is a continuous process that occurs inside the body throughout life. If we did not have stem cells, our lifespan would be about 1 hour, because there would be nothing to replace exhausted cells or damaged tissue.

Notably: any time the body is exposed to any sort of toxin, the inflammatory process causes stem cells to swarm the area to repair the damage.

While it is easy to think of stem cell therapy as some sort of magic, it is wise to implement strategies that nourish and optimize the stem cells we already have in your body.

Dr. Kristin Comella, a notable Stem Cell innovator, writes: You have to create an appropriate environment for these cells to function in. If you are putting garbage into your body and youre constantly burdening your body with toxins, your stem cells are getting too distracted trying to fight off those toxins. By creating an appropriate environment, optimizing your diet and reducing exposure to toxins, that will allow the stem cells that were putting in to really home in and focus on the true issue that were trying to treat.

The other thing weve discovered over the years is that [stem cell therapy] is not the type of thing where you take one dose and youre cured forever. Your tissues are constantly getting damaged Youre going to have to repeat-dose and use those stem cells to your advantage.

When you think about a lizard that loses its tail, it takes two years to grow back the tail. Why would we put unrealistic expectations on the stem cells that were trying to apply to repair or replace damaged tissue? This is a very slow process. This is something that will occur over months and may require repeat dosing.

Stem cells historically were isolated from bone marrow, and have been used for bone marrow transplants for cancer patients since the 1930s. However, we can get stem cells from just about any tissue in the body, every tissue contains stem cells.

Actually our marrow has very low amounts of mesenchymal stem cells, which are now believed to be the most important, from a therapeutic perspective.

Mesenchymal stem cells help trigger an immunomodulatory response or a paracrine effect, which means they send signals out to the rest of the body, calling cells to the area to help promote healing.

What weve discovered in more recent years is that a more plentiful source of stem cells is actually your fat tissue. [Body] fat can contain up to 500 times more cells than your bone marrow, as far as these mesenchymal type stem cells go.

One thing thats also critically important when youre talking about isolating the cells is the number of other cells that are going to be part of that population. When youre isolating a bone marrow sample, this actually is very high in white blood cells, which are pro-inflammatory, Ms. Comella writes.

White blood cells are part of the human immune response.

When an injury occurs, or a foreign body enters our system, white blood cells will attack. Unfortunately, white blood cells do not discriminate, and can create quite a bit of damage as they clean the area out.

Stem cells, in particular the mesenchymal cells, quiet down the white blood cells and then start the regeneration phase, which leads to new tissue. Bone marrow tends to be very high in white blood cells and low in the mesenchymal cells.

So, isolating stem cells from fat tissue is preferred not only because its easier on the patient, but fat also contains a higher population of mesenchymal cells and fewer white blood cells.

The benefit also of isolating [stem cells from] fat is that its a relatively simple procedure. Theres typically no shortage of fat tissue, especially in Americans, Dr.. Comella says. Also, as you age, your bone marrow declines with regards to the number of cells in it, whereas the fat tissue maintains a pretty high number of stem cells, even in older individuals.

Fat can be successfully harvested from just about anyone, regardless of their age or how thin they are. The procedure is done under local anesthesia, meaning that the patient stays awake. We can harvest as few as 15 cubic centimeters of fat, which is a very small amount of fat, and still get a very high number of stem cells.

A stem cell procedure can cost anywhere from $5,000 15,000, depending on what one is having done, and rarely if ever will insurance cover it.

Still, when compared it to the cost of long-term medications or the out-of-pocket cost of getting a knee replacement, stem cell therapy may still be a less expensive alternative.

Also, a single extraction will typically yield enough stem cells for 20 to 25 future treatments, should one decide to store his/her stem cells for future needs.

I think its accessible for patients, Dr.. Comella says. Its an out-patient procedure. You plan to be in clinic for about two hours; no real limitations afterwards, just no submerging in water, no alcohol, no smoking for a week. But other than that, patients can resume their normal activities and go about their regular daily lives.

She notes that patients who eat a very healthy diet, focusing on Organic and grass fed foods, have body fat that is very hearty and almost sticky, yielding high amounts of very healthy stem cells.

We can grow much better and faster stem cells from that fat than [the fat from] somebody who eats a grain-based diet or is exposed to a lot of toxins in their diet, she says. Their fat tends to be very fluffy, buttery yellow. The cells that come out of that are not necessarily as good a quality. Its just been very interesting. And of note, patients that are cigarette smokers, their fat is actually gray-tinged in color. The stem cells do not grow well at all.

What has been described above is whats called an autologous donation, meaning a person is getting the stem cells from oneself. A number of companies provide non-autologous donations using cells harvested from other people, typically women, like amniotic or embryonic mesenchymal cells.

This is an important distinction.

There are now just a couple of studies that have been published comparing an autologous source, meaning cells from you own body, to an allogeneic source, meaning cells from someone else.

So far, what has been discovered is that the autologous cells will outperform somebody elses cells inside ones body. This is not fully understood yet. It may be that the environment that ones own cells function in, and that they used to that environment. They recognize it. It is the same DNA and they can function well there.

But, once the culture is expanded and a pure population of these mesenchymal cells, not necessarily the sample thats coming right off of the liposuction, but a sample that has been taken to the lab and grown, those cells will not elicit an immune response if you use them in someone else. You could scientifically and medically use those in an unmatched person. However, there are some regulatory aspects of that with regards to the FDA.

In the US, there are a variety of new stem cell products available, referred to as amniotic, cord blood products or placenta products, which are prepared at a tissue bank. Such facilities must be registered with the FDA, and the products must undergo additional processing.

For example, they must be morselized, or snap frozen or blended in some way. Such processing typically breaks the membrane, releasing growth factors, and the resulting products are called acellular, meaning there are no living cells remaining in the sample.

The amniotic products available in the US are not so much stem cell products as they are growth factor products.

Dr. Comella notes: They can be useful in creating an immunomodulatory response, which can help to promote healing, but that still differs from the living stem cell procedures that can be done by either isolating cells from your fat or bone marrow. As a general rule, you do not achieve the clinical benefits when using an amniotic product, primarily because they do not contain living stem cells.

I want to contrast that to what are called embryonic stem cells, Dr. Comella adds. The products obtained from cord blood, from women who are having babies, are not embryonic stem cells. Embryonic stem cells are when you are first bringing the egg and sperm together. Three days after that, you can isolate what is called an inner cell mass. This inner cell mass can be used to then grow cells in culture, or that inner cell mass could eventually lead to the formation of a baby.

Those are embryonic stem cells, and those are pluripotential, meaning that they have the ability to form an entire being, versus adult stem cells or stem cells that are present in amniotic tissue, [which] are multipotential, which only have the ability to form subsets of tissue.

When youre dealing with different diseases or damaged tissue or inflammation, mostly you want to repair tissue. If somebody has damage in their knee, they dont necessarily need embryonic cells because they dont need a baby in their knee. They need new cartilage in their knee.

A common question is whether stem cells can cause overgrowth, leading to cancer or tumor formation.

As noted by Dr. Comella, this is a problem associated with embryonic stem cells, which tend to grow very rapidly and can form a teratoma because of the rapid cell growth. Adult stem cells, the cells obtained from ones own body, have growth inhibitions and will not form teratomas.

The theoretical concern that has been addressed in animal models or in petri dishes is that if you take cancer cells that are growing in a dish and apply stem cells, it may make those cancer cells grow more rapidly. But this does not translate in-vivo to humans.

If there was truly an issue with applying stem cells to a patient who has cancer, we would know about it by now, because weve been dosing cancer patients with stem cells since the 1930s. The safety profile is strong and there are tens of thousands of patients documented with these treatments, Dr. Comella says.

Another useful therapy is platelet-rich plasma (PRP).

Our peripheral blood contains platelets, which act as 1st responders when theres an injury. They come in and start the clotting mechanism, thereby preventing one from bleeding to death. They also give marching orders to other cells.

For example: platelets can command stem cells to multiply and grow, or to differentiate and form new tissue.

These platelets also have many different growth factors associated with them, which can help to promote healing and stop inflammation. PRP involves taking a blood sample and then spinning the blood in a centrifuge to isolate the platelets. The platelet-rich plasma is then injected back into the area that is inflamed.

One of the most common uses of platelet-rich plasma or PRP is in a joint. Now, platelets are going to be most successful in something that is rich in stem cells [such as] an acute or a very recent injury.

If you just hurt your knee, the first thing you should do is get PRP, because its going to help promote healing, and those platelets will attach to the surface receptors of the stem cells that are already going to the area to promote healing. It would be like putting fertilizer on your seed, which are the stem cells.

If you have something more chronic, this tends to be a stem cell-poor environment. In other words, you have osteoarthritis or youve got knee pain thats 5 years old and its been there for a long time; just putting PRP in it would be like putting fertilizer on dirt without planting a seed first.

The beauty of stem cell therapy is that it mimics a process that is ongoing in the human body all the time. Our stem cells are continuously promoting healing, and they do not have to be manipulated in any way. The stem cells naturally know how to home in on areas of inflammation and how to repair damaged tissue.

All were doing is harnessing the cells from one location where theyre sitting dormant and relocating them to exactly where we want them and we need them to work, Dr. Comella says. Basically, anything inside your body that is inflamed, that is damaged in some way, that is lacking blood supply, the [stem] cells can successfully treat.

That means orthopedics, knee injections, shoulder injections, osteoarthritis, acute injuries, anterior cruciate ligament tears in the back, back pain associated with degenerative disc disease or damaged tendons or ligaments, herniated and bulging discs. You can also use it in systemic issues, everything from diabetes, to cardiac, to lungs, any tissue organ inside your body that has been damaged.

Autoimmune diseases can also be treated. The stem cells are naturally immunosuppressant, meaning they can help quiet down an over reactive immune system and help the immune system function in a more normal way. Neurological diseases, traumatic brain injury, amyotrophic lateral sclerosis, Parkinsons. All of these have to do with tissue thats not functioning properly. The cells can be used to address that.

It is very impressive, the list of different diseases that could benefit from this intervention.

Again, it is not magic, but one can dramatically improve the benefits of this intervention by combining it with other healthy lifestyle factors that optimize mitochondrial function, such as eating a healthy Real food diet, exercising, sleeping well, avoiding toxins and detoxifying from toxic influences.

Stem Cells for Anti-Aging: Stem cells can also be used as part of an anti-aging program.

Dr. Comella has used stem cells on herself for several years, and report feeling better now than she did 10 year ago.

She writes,The ability to reduce inflammation inside your body is basically making yourself live longer. Inflammation is what kills us all. Its what makes our telomeres shrink. Its what causes us pain and discomfort. Its what makes the tissues start to die. The ability to dose yourself with stem cells and bring down your inflammation, which is most likely caused by any sort of toxin that youve been exposed to, breathing air is exposure to toxins, this is going to lengthen your lifespan.

I typically will do a dose every six to 12 months, regardless of whats going on. If I have anything that is bothering me, if I tweak my knee at the gym, then I absolutely will come in and do an injection in my knee. I want to keep my tissue healthy for as long as possible.

I want to stay strong. I dont want to wait until something is wrong with me. I think that this is the future of medicine. This is what were going to start to see. People will begin to get their regular doses of [their own] stem cells and itll just be common practice.

Keep in mind theres a gradual and progressive decline in the quality and the number of stem cells as we age, so if considering this approach, it would be to your advantage to extract and bank your stem cells as early on as possible. US Stem Cell provides a stem cell bank service, so one can store them until a later date when you might need them.

Your stem cells are never as young as they are right now. Every minute that you live, your telomeres are shrinking. The ability to lock in the youth of your cells today can be very beneficial for you going forward, and for your health going forward. God forbid something happens. What if you have a heart attack? Youre not going to get clearance to get a mini-lipo aspirate procedure.

If you have your cells waiting in the bank, ready for you, it becomes very easy to pull a dose and do an IV delivery of cells. Its almost criminal that were not doing this for every single one of our cardiac patients. This should be standard practice. We should be having every single patient bank their stem cells at a young age and have them waiting, ready and available. The technology is there. We have it. Im not sure why this technology is not being made available to everyone, she says.

I think stem cell therapy is very different than traditional medicine. Stem cell therapy may actually make it so that you dont have to be dependent on pharmaceutical medications. You can actually repair the tissue and thats it. This is a very different way of viewing medicine.

For a Physician in your area providing the service, you can go there. US Stem Cell can help you locate a qualified doctor.

Eat healthy, Be healthy, Live lively

blood, bodies, body, cell, cells, damage, grow, help, knee, patients, regenerate, repair, stem, tissue, USRM

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of The Red Roadmasters Technical Report on the US Major Market Indices, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

Go here to see the original:
Stem Cell Therapy: Repair and Regenerate Our Bodies - Live ... - Live Trading News

Posted in Cell Therapy | Comments Off on Stem Cell Therapy: Repair and Regenerate Our Bodies – Live … – Live Trading News

CAR T-Cell Therapy Effective in Multiple Myeloma – Cancer Network

Posted: June 10, 2017 at 3:44 am

Wanhong Zhao, MD, PhD, presenting results of the study; photo by ASCO/Scott Morgan 2017

A new type of immunotherapychimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation protein (BCMA)may be a new effective type of treatment for patients with multiple myeloma, according to the results of a single-arm study (abstract LBA3001) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 26.

Our results show clinical and reproducible therapeutic efficacy in refractory or relapsed multiple myeloma disease, said Wanhong Zhao, MD, PhD, an associate director of hematology at the Second Affiliated Hospital of Xian Jiaotong University in China, who presented the results.

With longer than 1 year of follow-up, early patients enrolled on the study are showing durable and stringent complete remissions, according to Zhao.

In recent years, CAR T-cell therapy targeting CD19 has been shown to be very effective in trials of acute lymphoblastic leukemia. However, there had been little success with CAR T-cell therapy targeting other biomarkers in other types of cancer.

Zhao and colleagues conducted a single-arm trial to assess the safety and efficacy of this treatment approach in patients with multiple myeloma. The presentation included data from the first 35 patients enrolled in the ongoing trial.

The overall response rate was 100%; 33 of the 35 patients (94%) had clinical remission of myeloma, with either complete response or very good partial response occurring within 2 months of undergoing CAR T-cell therapy. First signs of efficacy appeared as early as 10 days after treatment initiation.

Of the 35 patients, 19 have been followed for longer than 4 months. Of these patients, 14 have reached stringent complete response, 4 patients have achieved very good partial response, and 1 patient has achieved partial response.

In addition, there are 5 patients who have been followed for longer than 1 year; all of these patients remain in stringent complete remission and are free of minimal residual disease.

Cytokine release syndrome (CRS) is a common adverse effect related to CAR T-cell therapy. CRS occurred in 85% of patients. Among the 35 patients, 6 patients remained free of any CRS; 17 had grade 1, 10 had grade 2, and 2 had grade 3. No grade 4 or 5 CRS occurred and there were no treatment-related deaths.

According to Zhao, a US clinical trial of this technology is currently underway.

Commenting on the results of this study, ASCO Expert Michael S. Sabel, MD, FACS, of the University of Michigan, said that these results were revolutionary and show that immunotherapy is beginning to provide hope to patients with cancers that are not responding to standard chemotherapy.

You are now seeing a merger of immunotherapy with precision therapy and this is the epitome of personalized medicine, Sabel said. Now you see the ability to combine personalized medicine and immunotherapy to gear T cells to recognize patients own specific tumor. This opens the door to using precision immunotherapy to expand the potential of immunotherapy to a wider net of patients.

Read more:
CAR T-Cell Therapy Effective in Multiple Myeloma - Cancer Network

Posted in Cell Therapy | Comments Off on CAR T-Cell Therapy Effective in Multiple Myeloma – Cancer Network

Angela Bassett Talks Role in ‘Black Panther’, Diabetes – NBCNews.com

Posted: June 10, 2017 at 3:43 am

At 58, Oscar-nominated actress Angela Bassett has played a wide range of roles and now shes set to be part of the ground breaking new movie, Black Panther, the first Marvel Comic book movie to feature a black super hero.

Its thrilling you know, its all new to me, the whole super hero and huge franchise [movies], said Bassett. It was cast from actors from all over the globe. I think that fans have been asking for it, looking for it, expecting it, and youre going to be satisfied.

The movie is slated to hit theaters next year and casts Bassett as mother of superhero TChalla, the Black Panther. Bassett co-stars with Chadwick Boseman, Michael B. Jordan, and Lupita Nyong'o.

She was also recently cast in another big franchise movie: Mission Impossible 6.

Thats another one. Im like whats going on? I love it, its thrilling, said Bassett.

Related: Shape Shifter: Condola Rashad on Third Tony Award Nomination

Bassett revealed that she owes it all to her mother, Betty. It was her mother who pushed her to follow her dreams and gave her advice that she still remembers to this day.

Youre a prize, said Bassett. Think well of yourself. Every one is, but you are one and dont forget.

Her mother was her inspiration and its because of her mother that Bassett has taken on a new role to raise awareness about diabetes.

My mother had Type 2 diabetes as well as her brother, her eldest brother, said Bassett. At that time we were unaware about this link, this connection between Type 2 diabetes and heart disease which is what she passed from.

Actress Angela Bassett attends the panel discussion for Netflix's "Master of None" For Your Consideration Event at the Saban Media Center on June 5, 2017 in North Hollywood, California. (Photo by Alberto E. Rodriguez/Getty Images For Netflix) Alberto E. Rodriguez / Getty Images

In fact, Type 2 diabetes is linked to multiple complications. According to the Mayo Clinic, those affected with Type 2 diabetes are at higher risk not only for heart disease, but also for amputations, blindness, kidney damage and more.

There are more than 29 million Americans with Type 2 diabetes and it affects African-Americans at a higher than average rate. There is also a genetic link with the disease. Because of Bassetts family history, she revealed that she recently had a health scare during a yearly physical and has to pay attention to her diet and exercise.

Prevention and access to health care are key to keeping type two diabetes in check, said Bassett.

Related:

I think its extremely important. Its life and death. Whether you can see a doctor whether you can get your medication whether you can afford it."

In Bassett's latest role, she gets to play the advocate who could save real lives, off the movie screen.

Follow NBCBLK on

Here is the original post:
Angela Bassett Talks Role in 'Black Panther', Diabetes - NBCNews.com

Posted in Diabetes | Comments Off on Angela Bassett Talks Role in ‘Black Panther’, Diabetes – NBCNews.com

Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi – FierceBiotech

Posted: June 10, 2017 at 3:43 am

Lexicon Pharmaceuticals has posted upbeat data from another phase 3 trial of its Sanofi-partnered dual SGLT1 and SGLT2 inhibitor sotagliflozin. More patients in the treatment arm hit an established target for glycemic control than did in the control cohort, resulting in Lexicon chalking up its third phase 3 success for the diabetes tablet.

The latest trial enrolled 1,402 patients with type 1 diabetes and randomized them to receive either sotagliflozin or placebo. Going into the study the subjects had A1C levels ranging from 7% to 11%. Diabetes associations recommend that patients reduce their A1Clevels to below 7%. A1C is a marker that gives an average blood glucose level. The phase 3 trial assessed the proportion of participants in the sotagliflozin and placebo arms whose A1C levels fell to below 7% over 24 weeks of treatment.

Lexicon said the trial linked sotagliflozin to a statistically-significant improvement in the proportion of patients who met the A1C target. The finding adds to evidence that sotagliflozin helps patients with Type 1 diabetes to control their glucose levels.

Exactly how positive the data are is unclear. In the top-line release Lexicon said the trial met its primary endpoint but provided no details about what proportion of patients in each arm saw their A1C levels fall to below 7%. That datapoint will go some way to showing whether sotagliflozin can go beyond beating the placebo and establish itself as an effective treatment for type 1 diabetics.

The FDA and other regulators have already approved inhibitors of SGLT2, one of the targets hit by sotagliflozin, for use in type 2 diabetics. AstraZeneca and Bristol-Myers Squibbs Farxiga, Boehringer Ingelheim and Eli Lillys Jardiance and Johnson & Johnsons Invokana all compete for this niche.

Lexicon thinks sotagliflozin can improve on these existing therapies by also hitting SGLT1, which mediates the absorption of glucose in the intestines. SGLT2 plays a similar role in the kidneys.

Sanofi identified sotagliflozin as a way to enter and disrupt the nascent market for SGLT2 inhibitors in 2015, prompting it to pay $300 million upfront and up to $1.4 billion in milestones for the global license to the experimental drug. And with sotagliflozin having now come through three phase 3 trialsthe first two of which assessed the change in A1C from baselineit is nearing the day on which it can start recouping some of its outlay.

We look forward to pursuing regulatory submissions for the treatment of type 1 worldwide, Sanofi SVP Jorge Insuasty said in a statement.

Sanofi plans to pursue approvals of sotagliflozin in type 1 diabetes while developing the drug for use by people with the type 2 form of the condition. The French Big Pharma is running three phase 3 trials to assess the effect of sotagliflozin on the A1C levels of patients with type 2 diabetes. Sanofi expects to complete the trials in 2018 and 2019.

Go here to see the original:
Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi - FierceBiotech

Posted in Diabetes | Comments Off on Lexicon diabetes pill hits endpoint in another phase 3, teeing up regulatory filings by partner Sanofi – FierceBiotech

Study Shows Texting Could Help Type 2 Diabetes Management – NBC 7 San Diego

Posted: June 10, 2017 at 3:43 am

WATCH LIVE

A new study from the Scripps Whittier Diabetes Institute in La Jollashows that texting could be as good as medication at improving Type 2 Diabetes management.

The study looked at a low-income Hispanic community, known to have a high-rate of diabetes.

Lower income individuals sometimes dont havethe education to know what is the right approach to taking care of diabetes," said Dr. Athena Philis-Tsimikas, who spearheaded the study.

The 63 participants who were randomly assigned to the study group received 354 texts over six months--about two to three short messages a day.

Some of the reminder texts read: "Use small plates! Portions will look larger and you may feel more satisfied after eating."

Another text said, "Time to check your blood sugar. Please text back your results."

Ninety-sixpercent of the study group participants said the text messages helped them to manage their diabetes "a lot" by the time the trial ended.

"I lost weight," said Gloria Favela, a mural artist from Valley Center. "My blood sugars dropped. They were at a really healthy level.

Published at 9:49 PM PDT on Jun 9, 2017 | Updated at 10:08 PM PDT on Jun 9, 2017

Read the original:
Study Shows Texting Could Help Type 2 Diabetes Management - NBC 7 San Diego

Posted in Diabetes | Comments Off on Study Shows Texting Could Help Type 2 Diabetes Management – NBC 7 San Diego

News and announcements from the American Diabetes Association conference – MobiHealthNews

Posted: June 10, 2017 at 3:43 am

Diabetes management is a focus area for a number of digital health companies, and increasingly large medical device companies like Medtronic and Dexcom are turning to smartphone apps and connected devices for their consumer offerings. So its no surprise that at the 77th Scientific Sessions of the American Diabetes Association, which start today, there is a significant health tech presence. We didnt make it out to San Diego ourselves this year, but a lot of the digital health companies have already announced their major news from the conference. As we did last year were rounding up that news here, and well update this piece as more news breaks. Were even including a few news tidbits from this week that werent announced in connection with ADA but impact the diabetes space. Read on for the latest from small startups to major movers and shakers. Dexcom

Its been a big week in the news for the continuous glucose monitor maker. On Monday Dexcom got an important name drop at Apples WWDC: The company will be one of the first to take advantage of Apples addition of native Bluetooth to the Apple Watch. Dexcom has an Apple Watch app at the moment for users of its CGM, but it currently requires the phone to be in range. Now the Watch and the CGM will be able to communicate directly. Then on Wednesday the company announced its long-awaited Android app for Dexcom Share. The Android app just now received FDA clearance, and the company will roll it out this month. At the conference, Dexcom will announce an update to CLARITY, the companys diabetes management software platform. Dexcom is working with the International Diabetes Center (IDC) to incorporate the Ambulatory Glucose Profile, a report developed by IDC. AGP is a standardized way of reporting patient glucose data. AGP reports have been used for several years by physicians, Dr. George Grunberger, chairman of the Grunberger Diabetes Institute, explained in a statement. [It] presents the most relevant statistical and graphical information that would allow clinicians to quickly assess the glucose control of a patient and make meaningful clinical decisions. By having a wider adoption of this report by medical device companies, it allows the information to be agnostic to the manufacturer. AGP can become the EKG report of diabetology where there is one standard glucose report that all clinicians can interpret. One Drop

One Drop Medical, a direct-to-consumer diabetes management system that consists of a lancing device, test strips and a companion app, has expanded its subscription program and launched an Amazon Alexa integration. One Drop subscribers can command the voice assistant to track blood glucose, food and physical activity within the One Drop app, eliminating the need to manually enter any information.

"Accessibility is a foundational value at One Drop," One Drop CEO and founder Jeff Dachis said in a statement. "Now, with new voice and alternative visual interfaces, we are extending our commitment to accessible care with features and programs that allow access to data-driven diabetes care for those with vision challenges, advanced neuropathy, or limited dexterity/mobility, the elderly, caregivers, as well as those challenged by the visual/tactile interfaces associated with smartphones."

Additionally, One Drop is now offering two new specialized diabetes education and coaching programs one on how to deal with the burnout that comes from having a chronic condition, and another for advanced carb counting. The New York-based company will also share results from clinical studies of their system during the ADA conference. Medtronic

Medtronic will present results from several studies, ranging from clinical effectiveness of devices to how machine learning is impacting personalized diabetes management. Scientific presentations will cover insulin pump therapy performance for the MiniMed and SmartGuard systems as well as an update on the performance of SugarIQ, the app Medtronic developed with IBM Watson last year.

The app includes a manual food log and integrates data from Medtronic MiniMed Connect. As users record data about what they eat, when they use insulin, and their blood glucose levels, Watson machine learning generates predictive insights. Medtronic will also delve into notification and engagement strategies, such as in-clinic versus at-home management with email notifications. The company will also host a webcast on June 10 to update their diabetes product pipelines, market outlook and clinical data. T1D Exchange & Admetsys

Boston-based nonprofit T1D Exchange, which is solely focused on spurring innovation and research in type 1 diabetes, is now working withartificial pancreas technology provider Admetsys. The exact terms of the partnership werent disclosed, but T1D Exchange will allocate resources to continue the development of Admetsys Automated Insulin Delivery (AID) system for hospital use. The technology, which has been used in three clinical trials, uses a standard IV to draw a small blood sample every few minutes, measure glucose levels and return the blood back to the patient. From there, Admetsys creates a computational model to direct insulin dosages from syringe pumps. Glooko

Diabetes management company Glooko will detail results from two retrospective studies at ADA. The studies show that the Glooko mobile app led to a decrease in average blood glucose, estimated A1C (eA1C) and hyperglycemia rates in people with diabetes. Users of the mobile application also did more blood glucose testing than the control group.The drop in average blood glucose was 3.54 percent. App users were 4.38 percent less likely to experience hyperglycemic events. We are thrilled to see this additional clinical evidence that shows the positive impact Glooko can have on people with diabetes, Rick Altinger, CEO of Glooko, said in a statement. Glookos mission has always been to improve the clinical outcomes for people with diabetes by making diabetes management easier through digital tools. Our user satisfaction rates coupled with this clinical evidence adds credence to the investments that digital health companies have been making to improve the lives of people with chronic diseases. Ascensia & Voluntis Ascensia, a business unit created last year when Panasonic Healthcare Holdings acquired Bayer Diabetes Care, is now working with Paris, France-based app maker Voluntis. Ascensia makes the Contour Next One and Contour Next Link, a pair of connected glucometers that received FDA clearance last year, and Voluntis will develop an app called the Insulia Diabetes Management Companion for people with type 2 diabetes. The glucometers will connect via Bluetooth to the app, allowing blood glucose readings to be used to calculate insulin dosing.

Type 2 diabetes is a complex condition, especially for people using insulin therapy as part of their management. Were excited to be working together with Voluntis to empower people with Type 2 diabetes by helping them to better manage their insulin treatment, Ascensia CEO Michael Kloss said in a statement. This partnership helps us move further towards our ambition of providing integrated diabetes management, which we see as the future. It is our first partnership in the area of medication management, which is a critical component of integrated diabetes management, and we see Voluntis as a key partner in helping to deliver this goal.

DarioHealth

Israel-based smartphone-connected glucometer company DarioHealth isnt announcing data or new features at ATA but will announce a new social initiative called DarioCares. DarioHealth will donate a portion of its proceeds to charitable and nonprofit organizations working in the field of diabetes. "The ADA conference is one of the biggest annual events in the diabetes industry, Chairman and CEO Erez Raphael said in a statement. Many NGOs will be there and we look forward to strengthening our relationships with them and raising diabetes awareness. Furthermore, DarioCares is an excellent chance to play an active role with leading organizations that are driving change for people with diabetes. This is a win-win opportunity where we can make a significant contribution to the diabetes community."

Read the original:
News and announcements from the American Diabetes Association conference - MobiHealthNews

Posted in Diabetes | Comments Off on News and announcements from the American Diabetes Association conference – MobiHealthNews

ADA preview: 5 things to watch in diabetes – BioPharma Dive

Posted: June 10, 2017 at 3:43 am

The 77th Annual American Diabetes Association conference is set to begin today in San Diego. Running through Tuesday, the convention will highlight advances for the metabolic disease and likely bring further attention to ongoing issues that have been plaguing the space particularly, the rising cost of insulin and problems with patient adherence to treatment.

This years conference will include more than 15,000 participants looking to consume the 378 abstracts and 2,152 poster presentations. Much like the ADA conference last year, which was dominated by cardiovascular outcomes data for Eli Lilly & Co.s SGLT-2 inhibitor Jardiance (empagliflozin), some of the most pressing data will be further CV outcomes results.

The show isn't as relevant as it once was due to a dwindling diabetes pipeline, but there are still major pharma companies working diligently in the space. "This show has changed so much over the years because the business has changed so much. Diabetes drugs have really become commodities," said David Kliff long time investor, diabetic and author of industry newsletter the Diabetic Investor in an interview.

Here are several items from the conference that could get your blood sugar up:

Now that Lilly and Boehringer Ingelheim have garnered an updated label from the Food and Drug Administration for Jardiance that includes cardiovascular outcomes data from the EMPA-REG trial, other drugmakers are looking to prove that its a class-wide effect.

"If you look at Jardianceand the EMPA-REG data, which was really revolutionary it didn't really help them sales-wise," said Kliff. "This tells you about the power of the payer, it tells you that a lot of the experts believe it was a class-effect; these drugs are really becoming a commodity in a way."

Johnson & Johnson will be presenting data on Monday from its own cardiovascular outcomes trial for its SGLT-2 inhibitor Invokana (canagliflozin). The first in the class approved by the FDA, Invokana grew the market and has long been the market leader, but having outcomes data in hand has allowed Lilly and Boehringer to gain ground.

The 10,000-patient strong CANVAS clinical trial program will provide further insight into the cardiovascular benefits of one of diabetes youngest classes of drugs. Lilly and Boehringer will also be making six presentations beginning Saturday further discussing EMPA-REG.

J&J isnt the only company presenting cardiovascular outcomes data. Novo Nordisk will be presenting further data from the 7,000-patient DEVOTE study comparing its basal insulin Tresiba (insulin degludec) with long-time market leader Lantus (insulin glargine).

The initial results were announced last November and showed that Tresiba was non-inferior to Lantus although not superior. Although the Novo drug did show superiority on the secondary endpoint of hypoglycemia.

Novo Nordisk is now seeking approval from the FDA to get the info added to the label. Yet, the agency has been fairly strict with diabetes companies and hasnt considered things like hypoglycemia to be major differentiators.

Keep an eye out Monday for more insight on how the struggling Danish drugmaker might seek further differentiation from competitors.

Amgen and competitors Regeneron and Sanofi have been making headlines for two years now for their pricey cholesterol-lowering PCSK9 inhibitors. Those headlines have gotten ugly, as both Repatha (evolocumab) and Praluent (alirocumab) continue to struggle commercially. Those struggles are further compounded by the ongoing legal battle between the companies over patent rights.

Diabetes is an area that PCSK9 inhibitors have only dabbled in. The high-risk patient population has been included minimally in previous clinical trials, but new data to be presented on Sunday will focus on trials specifically geared toward diabetes patients.

Previous clinical data has shown correlations between PCSK9 levels and insulin levels, but the new studies will look at the safety, tolerability and efficacy in the glycemic-related endpoints.

If the PCSK9 inhibitors are successful in this patient population, then this could be the commercial boost that these players need to finally make a dent in the market.

Both Apple and Google have been moving beyond their respective realms of computer hardware and the internet to get into healthcare.

While neither company has yet to enter the realm of clinical trials and drug development, they are about to make a splash on the diabetes landscape. Apple has partnered up with Dexcom to bring constant glucose monitoring to the Apple Watch. This addition could be a major advancement for patient adherence, allowing patients to have easier access to glucose numbers and better monitor their blood sugar.

Meanwhile, Googles sister company Verily teamed up with Sanofi to launch OnDuo, a company meant to combine Verilys software expertise with Sanofis diabetes experience to bring disease management solutions to patients.

Both of these deals are part of a larger trend toward using technology to bring better drug adherence solutions to patients. Technology is bringing to patients tools such as smart pill bottles to help them track doses, and cell phone apps that give them reminders about both taking medications and getting to physician appointments.

One of the many symposia to be presented throughout the long-weekend will deal with the rising cost of insulin. On Saturday, conference goers will be able to hear about how the diabetes staple has risen in price and what it means for the market and patients.

Companies including Novo Nordisk, Lilly and Sanofi have been under fire even facing law suits over how insulin prices have risen in recent years.

Yet, some in the industry argue the pharma companies arent to blame, that they are just complying with market forces while dealing with a complex payment system. "This isn't simple math, it's algebra. There are just tons of variables," said Kliff. "Insulin really doesn't cost too much. People get lost in the cash-paying side of the market, which is small percentage. If you have insurance it costs like nothing. A lot of patients don't understand rebates and net prices and all these other things."

While the industry will continue to point to the third-party payers as the evil doers of pricing, expect that debate to rage on, especially as more biosimilar insulins enter the market and put further pressure on pricing dynamics.

Continue reading here:
ADA preview: 5 things to watch in diabetes - BioPharma Dive

Posted in Diabetes | Comments Off on ADA preview: 5 things to watch in diabetes – BioPharma Dive

Page 1,542«..1020..1,5411,5421,5431,544..1,5501,560..»